Theralase(r) closes non-brokered private placement equity financing

Toronto, on / accesswire / june 30, 2023 / theralase® technologies inc. ("theralase®" or the "company") (tsxv:tlt) (otcqb:tltff), a clinical stage pharmaceutical company focused on the research and development of light activated photo dynamic compounds ("pdcs") and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, is pleased to announce that it has successfully closed a non-brokered private placement offering ("offering") of units ("units"). on closing, the corporation issued an aggregate of 4,800,000 units at a price of $0.25 per unit for aggregate gross proceeds of approximately $can 1,200,000.
CAN Ratings Summary
CAN Quant Ranking